Treatable traits approach for personalised management of sarcoidosis Authors: Francesco Amati, Anna Stainer, Letizia Corinna Morlacchi, Rocco Francesco Rinaldo, Davide Biondini, Francesco Blasi, Paolo Solidoro, Stefano Aliberti, Paolo Spagnolo Published: 2026 ABSTRACT AbstractIn sarcoidosis, personalised strategies that consider the various phenotypes and endotypes of the disease have the potential to improve patient care. The ‘treatable traits’ (TT) approach offers a promising strategy that has already been proposed and implemented in several other chronic pulmonary diseases. In this review, we propose five distinct TT categories for patients with sarcoidosis: aetiological, lifestyle, pulmonary, extrapulmonary (systemic) and comorbidities.Despite the potential of this strategy, several challenges hinder its implementation. In addition, much of the knowledge on the definition and prevalence of TTs comes from single-centre studies. Creating international registries will enhance our understanding and provide more accurate data on these traits.TTs are dynamic and require continuous evaluation to effectively respond to changes caused by disease progression or treatment response. A multidisciplinary management approach is therefore crucial as sarcoidosis can impact multiple organs. Integrating primary care physicians into the management framework will improve overall patient care.Incorporating patient preferences into the TT strategy is vital for improving adherence to treatment. Additionally, using patient-reported outcome measures will provide valuable insights into the impact of treatment.While the TT approach is feasible in developed healthcare systems, challenges exist in resource-limited settings. Advancing patient-centred care towards 5P medicine involves addressing key TTs that meet the unique patient needs.Therefore, randomised controlled trials focused on TTs are needed. Our proposed TT strategy aims to enhance quality of life and outcomes for patients with sarcoidosis while increasing awareness of the importance of TTs among healthcare providers and advocacy groups. Introduction Sarcoidosis is a chronic, systemic, inflammatory disease characterised by the accumulation of non-caseating granulomas in affected organs.1 According to the prevailing hypothesis, granulomas develop in response to an as yet unidentified antigen (or antigens) in genetically predisposed individuals.1 2 The clinical presentation, natural history and prognosis of sarcoidosis are variable and unpredictable.2 While spontaneous resolution may occur in up to one-third of patients, others may progress to develop significant chronic complications, including pulmonary fibrosis, renal failure, dysrhythmias and/or neurosarcoidosis.3 4 This variability is likely influenced by genetic factors, environmental exposures and socioeconomic status.5 Several phenotypes of sarcoidosis have been identified based on distinct patterns of organ involvement and variations in disease onset and progression.6 7 Furthermore, robust associations between single nucleotide polymorphisms (SNPs) and disease onset and behaviours have been identified, suggesting the existence of distinct pathways (ie, endotypes) within sarcoidosis.8 The concept of ‘endophenotype’ has recently gained attention, reflecting the increasing acknowledgement of the role of genetics in disease manifestation.9 A Delphi consensus has established a scheme to guide therapeutic interventions that consider different levels of treatment based on the clinical course of sarcoidosis patients.10 However, the management of sarcoidosis remains challenging due to several factors, including the limited number of randomised controlled trials (RCTs) conducted in this disease, the reliance on low-quality evidence to guide treatment, the lack of tools to predict treatment response and the impact of comorbidities, psychosocial factors and lifestyle on disease natural history and outcomes.10–13 Thus, personalised approaches based on phenotypes and endotypes should be implemented in patients with sarcoidosis. To fill this gap, a ‘treatable traits’ (TTs) approach represents a promising strategy. A TT is defined as a clinically relevant phenotypic or endotypic characteristic that can be assessed and potentially targeted by an intervention with the aim of improving a related clinical outcome.14 This strategy aims to classify treatable targets based on their nature and to treat patients accordingly in a precision medicine fashion.15 This approach has already been proposed and implemented in several pulmonary diseases as well as connective tissue disorders, such as systemic sclerosis.16–20 In this review, we propose five different categories of TT in patients with sarcoidosis: etiological, lifestyle, pulmonary, extrapulmonary (systemic) and comorbidities (table 1). Given the heterogeneity in the strength of evidence supporting individual traits, we have stratified them according to their level of evidence (established, emerging or speculative) to better reflect their current clinical applicability and to align with the original definition of TTs. In the following paragraphs, examples of TTs for each category will be provided and discussed. Table 1 summarises the proposed TTs. Table 1Treatable traits (TTs) in sarcoidosis categorised in aetiological, lifestyle, pulmonary, extrapulmonary and comorbiditiesTreatable traitAssessment tool(Potential) Treatment optionExpected benefits of treatment*Level of evidenceAetiological/risk factors ObesityBMIWaist circumferenceWaist-hip ratioDiet instructionsPulmonary rehabilitationBariatric surgeryPrevent or reduce the risk of sarcoidosis development and progressionImprove QoLImprove exercise toleranceSpeculativeLifestyle Adherence to treatmentPatient and relatives’ feedbackMedication Adherence Report ScaleEducationWritten instructionsSelf-managementFamily and social supportImprove outcomesImprove QoLEstablished Lack of exercise/deconditioning of skeletal muscleCardiopulmonary exercise testing6MWTPrescribed exercise programmesPulmonary rehabilitationImprove QoLImprove lung functionImprove exercise capacityEstablished DietPatient-reportedNutritional questionnairesDiet instructionsImprove the quality of lifePotentially modulate systemic inflammationManagement of hypercalcaemiaManagement of steroid-related side effectsSpeculativePulmonary Non-fibrotic involvementPatient-reported symptomsPulmonary function testsHRCTLab testsBronchoscopy with BALLung biopsyMonitoringSystemic therapyTreat symptomsImprove lung functionImprove QoLPrevent progression and fibrosisEstablished Progressive fibrotic involvementPatient-reported symptomsPulmonary function testsHRCTLab testsLung biopsyOptimisation of therapyConsider antifibroticsReferral to lung transplant centreReduce/stabilise symptomsSlow lung function declineImprove QoLReduce mortalityPrevent exacerbationEmerging Chronic respiratory failureABG6MWTPolysomnographyLong-term oxygen therapyNon-invasive ventilationReferral to lung transplant centrePulmonary rehabilitationPalliative careImprove QoLReduce symptomsImprove survivalEstablished Intractable chronic coughPatient-reported symptomsScores (LCQ, VAS, CQLQ)AntitussiveThalidomideGabapentinImprove QoLEmerging Airway obstructionPulmonary function testsBronchodilatorsSystemic and/or inhaled steroidsImprove lung functionImprove QoLReduce/stabilise symptomsEstablishedPulmonary disease states Acute exacerbationHRCTBronchoscopy with BAL (microbiological and cytological sampling)Lab testsSystemic glucocorticoidsConsider antifibroticsImprove survivalEstablished Relapsing diseaseHRCTBronchoscopy with BAL (microbiological and cytological sampling)Lab testsSystemic glucocorticoidsAdjust immunosuppressionConsider antifibroticsReduce/stabilise symptomsSlow lung function declineImprove QoLReduce mortalityEstablishedExtrapulmonary and systemic involvement Skin granulomatous specific lesionsClinical evaluationSkin assessment tools (SASI, CSAMI)Skin biopsy histology (granulomas)Skin biopsy culturesTopic therapySystemic therapyImprove QoLPrevent scarringEstablished Erythema nodosumClinical presentationConsider skin biopsy (panniculitis)Systemic therapyImprove symptomsImprove QoLEstablishedLymphadenopathyCT scanEchographyBiopsyMonitoringSystemic therapyDebulking of massivelymphadenopathyEmerging Spleenic involvementCT scanEchographyComplete blood count (screening hypersplenism)MonitoringSystemic therapyConsider surgery for refractory hypersplenismImprove symptomsTreat hypersplenismEmerging UveitisClinical historyEye examinationOphthalmic imagingTopic therapySystemic therapyTreat/improve symptomsPrevent loss of visionEstablished Lacrimal, orbital, scleral or optic nerve diseaseClinical historyEye examinationOphthalmic imagingConsider conjunctivae, lacrimal glands or orbital tissues biopsyTopic therapySystemic therapySurgery for orbital involvementTreat/improve symptomsPrevent loss of visionSurgical correction of strabismus and/or abnormal eyelid positionEmerging Gastrointestinal (oral, oesophageal, gastric, bowel)Clinical historyUpper GI endoscopy and biopsyLower GI endoscopy and biopsyCT scanFDG-PETFollow-upSystemic therapyConsider surgery (stenotic lesions)Treat/improve symptomsEmerging Liver involvementCT scanFDG-PETBlood examinationLiver biopsyAbdomen echo (evaluate involvement, screen portal hypertension)Follow-upSystemic therapyLiver transplantTreat/improve symptomsTreat/prevent portal hypertensionPrevent cirrhosis and end-stage diseaseEmerging CNS involvementClinical historyNeurological examinationCNS MRI with contrast enhancementLumbar punctureBiopsy (rarely indicated)Systemic therapyConsider surgical resection in case of CNS mass lesionCorrection of endocrinologic deficiencies in case of hypothalamic involvementTreat/improve symptomsImprove QoLEstablished Small fibre neuropathySmall fibre neuropathy screening listBiopsy of the skinIVIGAnti-TNFCibinetideTreat/improve symptomsImprove QoLSpeculative Upper respiratory tractClinical historyEndoscopyBiopsySystemic therapyIntralesional therapyTopic therapySurgical treatmentTreat/improve symptomsEmerging Cytopenias related to bone marrow involvementBlood examinationsFDG-PETBone marrow biopsySystemic therapyTreat/improve symptomsEmerging MusculoskeletalClinical presentationUltrasonography and MRI studies of involved jointsSynovial biopsySystemic therapySynovectomy (in selected patients with disease resistant to medical therapy)Treat/improve symptomsImprove QoLEstablished Hypothyroidism related to thyroid involvementClinical presentationBlood examinations for thyroid dysfunctionThyroid echographyFollow-upThyroid hormone replacement therapyTreat/improve symptomsEstablished Hypercalcaemia, hypercalciuriaLab examinationAbdominal echoSystemic therapyTreat/improve symptomsPrevent nephrocalcinosis and CKDEstablished MyocarditisClinical historyCardiac biomarkersECGEchocardiographyPETCardiac MRISystemic therapyICD implantTreat symptomsImprove QoLPrevent sudden cardiac deathReduce mortalityEstablished PH (group V)EchocardiographyRHCSupportive therapyConsider only in selected cases Riociguat or BosentanImprove QoLImprove exercise capacityEmergingComorbidities Sarcoidosis-associated (organ complication) GERDSymptomsOesophageal pH monitoringManometryUpper endoscopyDiet instructionsPPIs, H2-receptor antagonists, pro-kineticsFundoplicationImprove outcomesReduce lung damageEmerging PH (group III)EchocardiographyConsider RHCReferral to lung transplant centreTrial with PH targeted therapies in selected patients (eg, treprostinil)Oxygen/non-invasive ventilationImprove QoLImprove outcomesReduce mortalityEmerging Congestive heart failureNT-proBNPEchocardiographyCoronary angiographyTargeted pharmacological treatmentICD implantationImprove QoLReduce mortalityEstablished OSASleep studyDiet instructionsCPAP treatmentImprove QoLReduce mortalityEstablished Lung cancerHRCTFDG PETBiopsySurgical resectionRadiotherapyChemotherapyReduce mortalityEstablished Pulmonary embolismCT pulmonary angiogramAnticoagulantsReduce mortalityEstablished Cachexia/malnutritionBMIPre-albuminTransferrinNutritional supportPulmonary rehabilitationImprove QoLEstablished FrailtyFFP binary scoreFrailty IndexNutritional supportivePulmonary rehabilitationPhysical activity programmesImprove QoLReduce mortalityEmerging Anxiety/depressionPatient reportedscores (eg, HADS)Counselling/cognitive behavioural therapyAntidepressant/AnxiolyticsPulmonary rehabilitationImprove QoLImprove adherence to treatmentEstablished FatigueFASPsychological supportPulmonary rehabilitationPhysical activity programmesNeurostimulantsArmodafinilImprove QoLEmergingTreatment-induced DiabetesFasting glucose persistently above 125 mg/dLRandom glucose levels above 200 mg/dL occurring in the context of high-dose glucocorticoid therapyDiet instructionsLifestyle instructionsInsulinOral hypoglycaemicsImprove QoLReduce systemic complication of diabetesReduce mortalityEstablished Osteoporosis/osteopeniaBone densitometryDiet instructionsLifestyle instructionsPharmacological therapyImprove QoLReduce risk of fracturesReduce mortalityEstablishedABG, arterial blood gas analysis; BAL, bronchoalveolar lavage; BMI, body mass index; CKD, chronic kidney disease; CNS, central nervous system; CPAP, continuous positive airway pressure; CQLQ, Cough Quality of Life Questionnaire; CSAMI, Cutaneous Sarcoidosis Activity and Morphology Instrument; EKG, electrocardiogram; FAS, Fatigue Assessment Scale; FFP, fried frailty phenotype; GERD, gastroesophageal reflux disease; GI, gastrointestinal; HADS, Hospital Anxiety and Depression Scale; HRCT, high resolution CT; ICD, implantable cardioverter defibrillator; IVIG, intravenous immunoglobulin; LCQ, Leicester Cough Questionnaire; 6MWT, 6-minute walking test; NT-proBNP, N-terminal pro b-type Natriuretic Peptide; OSA, obstructive sleep apnoea; PET, positron emission tomography; PET FDG, fluorodeoxyglucose positron emission tomography; PH, pulmonary hypertension; PPI, proton pump inhibitor; QoL, quality of life; RHC, right heart catheterisation; SASI, Sarcoidosis Activity and Severity Index; TNF, tumour necrosis factor; VAS, visual analogue scale. Treatable traits (TTs) in sarcoidosis categorised in aetiological, lifestyle, pulmonary, extrapulmonary and comorbidities ABG, arterial blood gas analysis; BAL, bronchoalveolar lavage; BMI, body mass index; CKD, chronic kidney disease; CNS, central nervous system; CPAP, continuous positive airway pressure; CQLQ, Cough Quality of Life Questionnaire; CSAMI, Cutaneous Sarcoidosis Activity and Morphology Instrument; EKG, electrocardiogram; FAS, Fatigue Assessment Scale; FFP, fried frailty phenotype; GERD, gastroesophageal reflux disease; GI, gastrointestinal; HADS, Hospital Anxiety and Depression Scale; HRCT, high resolution CT; ICD, implantable cardioverter defibrillator; IVIG, intravenous immunoglobulin; LCQ, Leicester Cough Questionnaire; 6MWT, 6-minute walking test; NT-proBNP, N-terminal pro b-type Natriuretic Peptide; OSA, obstructive sleep apnoea; PET, positron emission tomography; PET FDG, fluorodeoxyglucose positron emission tomography; PH, pulmonary hypertension; PPI, proton pump inhibitor; QoL, quality of life; RHC, right heart catheterisation; SASI, Sarcoidosis Activity and Severity Index; TNF, tumour necrosis factor; VAS, visual analogue scale. Aetiological TTs and risk factors Recent advances in genetic research have significantly deepened our understanding of the role of the human leucocyte antigen (HLA) and non-HLA genes in the pathogenesis and prognosis of sarcoidosis. Genome-wide association studies (GWAS) and high-resolution HLA typing have revealed that certain HLA alleles and SNPs confer susceptibility to sarcoidosis, while others are protective or associated with specific clinical phenotypes. Notably, a GWAS involving over 2500 European-ancestry individuals identified 49 SNPs within the HLA region that were significantly associated with sarcoidosis susceptibility.21 HLA-DRB1*0101, DQA1*0101 and DQB1*0501 emerged as prominent risk factors; they may be important in modulating antigen presentation and subsequent T-cell mediated immune responses that are key elements in the pathogenesis of sarcoidosis. Earlier studies also supported this association. A previous study identified SNPs within HLA-DRA and BTNL2 genes as key contributors to disease development, independent of HLA alleles.22 These SNPs were further shown to act as expression quantitative trait loci, suggesting they may influence disease risk through gene regulation rather than structural variation in HLA proteins. Moreover, a population-based study in Finland highlighted the relevance of extended MHC haplotypes, such as HLA-DRB1*04:01-DPB1*04:01, in conferring susceptibility, reinforcing the hypothesis that the cumulative effect of multiple linked variants may better explain disease risk.23 While these findings provide important insights into disease susceptibility and pathophysiology, they are primarily derived from observational and population-based studies and are not yet clinically actionable. In addition, most of these genetic associations have been described predominantly in populations of European ancestry, which may limit their generalisability to other ethnic groups.23 Yet, the pathophysiological implications of these findings might be significant, especially when considering their potential to inform personalised therapeutic strategies. In this regard, it has been consistently shown that the DRB1*0301/DQB1*0201 allele is associated with acute, self-limiting disease (eg, Löfgren’s syndrome).22 23 These associations should be interpreted with caution, as they do not translate to change in clinical decision-making. However, the existence of distinct immunological routes driven by HLA-mediated antigen processing could be exploited therapeutically. Theoretically, patients carrying alleles associated with chronic disease may benefit from early initiation of immunomodulatory therapies such as tumour necrosis factor (TNF)-α inhibitors, although this remains speculative and not supported by clinical trials of patients stratified by genetic background. Although clinical trials of patient subsets stratified based on their genetic background are lacking, the growing body of evidence in this field provides a compelling rationale for such an approach. Future research integrating genomic, transcriptomic and proteomic data is essential to develop predictive biomarkers and implement them in individualised treatment algorithms. The chronic systemic inflammation caused by obesity may have a role in developing several diseases, including sarcoidosis. Leptin, which is a pro-inflammatory adipokine, has a potent immunomodulatory effect that can sustain autoreactive cell proliferation, thereby increasing the risk of autoimmunity and sarcoidosis.24 In addition to adipocytes, adipose tissue consists of several types of innate and adaptive immune cells contributing to its metabolic and immune function.25 Obese adipose tissue expands with obesity and undergoes shifts in the populations of resident immune cells, with loss of anti-inflammatory cytokines and secretion of proinflammatory cytokines (eg, TNF-α, interleukin (IL)-6).26 Moreover, in obese patients, this switch influences the immune cell phenotype of the lungs, generating a proinflammatory environment that may trigger the granulomatous inflammation of sarcoidosis.27 The first evidence of obesity as a risk factor for sarcoidosis was reported in a Danish registry-based study, in which women with a high body mass index (BMI) had a significantly higher risk of developing sarcoidosis compared with healthy women.28 This association has been confirmed in a study of African-American women and a registry-based study that included predominantly Caucasian patients.29 30 A large cohort study including more than 100 000 subjects, predominantly white women (96%), found a higher risk of sarcoidosis in obese or overweight participants who had no history of disease at the start of the observation period. Moreover, individuals who experience greater weight gain, particularly during adulthood, are more likely to develop sarcoidosis compared with those who maintain a stable weight.31 Conversely, a recent retrospective study that analysed over 10 000 US veterans with a diagnosis of sarcoidosis found no association between BMI and disease onset. However, BMI may not accurately reflect the proportion of lean versus fatty mass, given the evidence that men tend to have higher lean mass than women even when they have the same BMI, and BMI does not measure central adiposity.32 As recently suggested, future studies should incorporate additional anthropometric measures (eg, waist circumference), as BMI alone may not reliably reflect obesity as a risk factor for sarcoidosis.33 Obesity might amplify the symptoms of sarcoidosis, with studies showing poorer perceived health status and health-related quality of life (QoL) compared with non-obese patients. Indeed, a recent study that used the King’s Sarcoidosis Questionnaire found that higher BMI was significantly associated with lower general health status scores, suggesting that obesity negatively affects QoL in these patients.34 Moreover, treatment of sarcoidosis with corticosteroids can lead to weight gain, sustaining obesity-related inflammation.34–37 Thus, obesity represents a modifiable TT that has a profound influence on several other traits, even though the role in sarcoidosis development needs to be confirmed. Lifestyle TTs Sarcoidosis is associated with poor treatment adherence. Indeed, it frequently has a chronic course and may require long-term corticosteroid or immunosuppressive treatments that are associated with substantial toxicity.34 38 Up to two-thirds of patients may not adhere to treatment.39 The use of self-reported measures of adherence could be an important tool to address this problem. However, they are susceptible to ‘social appeal’ bias and may underestimate the real adherence as it was reported in other chronic respiratory diseases.40–42 With these limitations, self-reported measurements are important to identify patients less likely to adhere to treatment. However, they should be coupled with an open and thorough communication between patient and physician with the aim of addressing uncertainties about the disease and patient expectations. Patients with sarcoidosis often report, as the main point of criticism in their relationship with the treating physician, the insufficient assistance given with the management of treatment side effects. Some patients feel that doctors were prescribing medications only for financial gain.43 The ability of the physician lies in tailoring the communication to each patient. As an example, in those that may have a cognitive impairment or forgetfulness, it could be important to involve the family as a caregiver or give simple written instructions, especially about adverse effects of medications. Side effects are often a major concern and cause of non-adherence, especially among patients treated with corticosteroids. The patient concerns about the use of medications should be discussed with the physician to reduce the perception that treatment is neither patient-centric nor tailored to the patient needs.44 45 The goal of obtaining a higher adherence to treatment is to improve health-related QoL, although a better QoL may also facilitate adherence to treatment.45 The TT approach might help patients with sarcoidosis better understand their disease and has the potential to avoid inappropriate treatment when specific traits have been ruled out or corrected. An individualised approach might also encourage patient engagement in shared decision-making, aligning patient expectations with the treatment plan thus avoiding patient frustration.46 Finally, it is important to highlight the role of patient associations in promoting patient-centred strategies, contributing to practice guidelines for treatment, improving patient QoL and reducing confusion and isolation by providing accessible information about the disease. Pulmonary TTs Pulmonary involvement in sarcoidosis occurs in the vast majority of patients and is characterised by heterogeneous clinical and radiological features.47 48 Some patients may experience an asymptomatic disorder, often discovered incidentally, while others may develop progressive fibrosis refractory to conventional treatment and associated with a poor prognosis.47 Dyspnoea and cough are the most common symptoms. The frequency of cough in sarcoidosis varies significantly across different populations, with reported prevalence ranging from 3% to 53%.49 Studies indicate that cough severity is associated with ethnicity and sex but not with spirometry, Scadding stage, smoking history or age.50–52 Moreover, cough could be a sensitive but not specific marker of sarcoidosis activity.53 In pulmonary sarcoidosis, cough has been associated with different mechanisms and causes, including airway irritation and structural airway damage resulting directly from granulomatous inflammation, cough reflex hypersensitivity, airway distortion from fibrosis, bronchiectasis and airway clearance impairment, and upper airways involvement.54 The characteristics of cough in sarcoidosis vary depending on its underlying cause, and cough is frequently associated with poor QoL.55 The management of sarcoidosis-associated cough depends on its aetiology and includes inhaled and systemic corticosteroids, bronchodilators, airway clearance techniques and treatment of concomitant pulmonary infections.56 In cases of refractory chronic cough, gabapentin and multimodality speech pathology therapy could also be considered.57 From a functional point of view, pulmonary sarcoidosis is typically associated with a restrictive ventilatory defect due to parenchymal disease or fibrosis.58 However, an obstructive pattern is also common. Indeed, endobronchial sarcoid granulomas can narrow, distort or rarely obstruct the airways.59 Moreover, endobronchial granulomatous inflammation can progress to airway scarring leading to airflow obstruction.60 When airway involvement is present, the decision to initiate empirical therapy is guided by the severity and progression of symptoms. Notably, abnormal pulmonary function tests are not an indication for treatment in the absence of symptoms.61 From a radiological point of view, seven high-resolution CT (HRCT) phenotypes broadly clustered in two categories, non-fibrotic and fibrotic, have been recently described.47 Extensive fibrosis on HRCT has been associated with increased mortality along with other factors such as reduction in forced vital capacity (FVC), pulmonary hypertension (PH) and advanced age.7 62 63 A progressive phenotype—referred to as progressive pulmonary fibrosis (PPF)-interstitial lung disease (ILD)—and a usual interstitial pneumonia (UIP)-like pattern on HRCT are independent predictors for mortality. Notably, only a small proportion of sarcoidosis patients develops PPF.64 65 The mechanisms leading to PPF are not fully understood, but fibrosis in sarcoidosis seems to be a distinct clinicopathological entity, rather than a continuum in the acute inflammatory process.66 67 The clinical and radiological features of PPF have many overlapping characteristics irrespective of the underlying aetiology and explanted lungs show augmentation of several factors associated with fibroblast proliferation across PPF ILDs, including sarcoidosis.68 69 Patients with a PPF might be amenable to anti-fibrotic treatment. Similar to IPF, nintedanib, an intracellular tyrosine kinase inhibitor reduces the rate of disease progression, as measured by the decline in FVC, irrespective of the underlying ILD diagnosis in patients with PPF.70 In particular, nintedanib is efficacious in slowing disease progression in patients with both UIP and non-UIP pattern on HRCT.70 However, the INBUILD trial included only a small number of sarcoidosis patients with a progressive phenotype. Although some biomarkers have been described in patients with a PPF or with end-stage disease, there are no reliable predictors of response to antifibrotic therapy.71 72 Thus, PPF represents a relevant TT in sarcoidosis that should be further analysed. However, the clinical course of fibrotic pulmonary sarcoidosis is highly heterogeneous, and many patients remain stable despite extensive radiological fibrosis on HRCT.73 In addition, lesions such as nodules, ground-glass opacity, interlobular septal thickening and consolidation herald a non-fibrotic disease potentially responsive to treatment.59 74 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) can help differentiate fibrotic from active/non-fibrotic disease.75 From this perspective, identifying patients with active disease is crucial, as they are more likely to benefit from anti-granulomatous treatment. Extrapulmonary TTs Due to the systemic nature of the disease, a comprehensive assessment of patients with sarcoidosis is crucial. Sarcoidosis-associated pulmonary hypertension (SAPH) is a rare but severe disease complication that results from multiple mechanisms.76 77 SAPH is included in group 5 of the PH classification, which includes PH with unclear and/or multifactorial mechanisms.76 Potential and possibly coexisting pathogenetic mechanisms include: vasculitis, granulomatous vascular involvement, veno-occlusive disease, pulmonary embolism, ILD (parenchymal disease due to granulomas and/or fibrosis), pulmonary artery/vein extrinsic compression, fibrosing mediastinitis but also extrapulmonary causes such as left ventricular dysfunction, sleep apnoea or liver diseases and portal hypertension.77 Thus, it is of utmost importance to identify a dominant cause for SAPH in individual patients. SAPH phenotyping is a dynamic process with several potential evolving phenotypes. While immunosuppression is a fundamental part of disease management, a careful assessment of the mechanisms involved in the development of PH (with particular attention on excluding post-capillary conditions), the severity of PH and the severity of the underlying parenchymal lung disease (FVC <50% predicted) must be carefully assessed before a trial with specific pulmonary vasodilators is considered.77 However, there are no conclusive data on the efficacy of specific pulmonary arterial hypertension (PAH) drugs in these patients,77–79 with only two small double-blind placebo-controlled trials showing the efficacy of Riociguat in improving time to clinical worsening at 1 year and exercise capacity,80 and Bosentan in improving pulmonary haemodynamics.81 Thus, off-label use of PAH therapies should be considered on a case-by-case basis.77 Although as many as 25% of sarcoidosis patients are believed to have cardiac involvement, clinically overt disease is encountered in about 5% of cases.82–84 Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous inflammation of the myocardium and may cause a number of clinical manifestations, including right or left ventricular dysfunction (both diastolic and systolic), high-grade conduction disease or ventricular arrhythmias.84 85 The choice to institute treatment should be based on the level of diagnostic confidence (ie, definite when based on histology or highly probable based on cardiac magnetic resonance and/or positron emission tomography findings).86 Beyond other medical treatment as indicated (antiarrhythmics, device placement, standard heart failure treatment), glucocorticoids remain the drugs of choice as they have been shown to reduce the risk of important composite cardiac outcomes.85 87 Other treatments, intended both as steroid-sparing or as immunosuppressant, include methotrexate, azathioprine, mycophenolate mofetil, infliximab, adalimumab or cyclophosphamide, although the scarcity of data on their efficacy and safety in this setting does not allow drawing recommendations on their use.87 Comorbidity TTs In a patient with a given index disease, comorbidity refers to any additional coexisting ailment. Comorbidity may alter the clinical course of patients with the same disease, affecting the time of diagnosis, prognosis, treatment decisions and outcomes.88 In sarcoidosis, several conditions may coexist in the same patients, making it difficult sometimes to differentiate between complications and concomitant conditions. Therefore, it is crucial to perform a thorough assessment of any specific disorder possibly associated with sarcoidosis.89 Such an approach is even more important whenever the disease progresses and in patients who are referred for lung transplant. The International Society for Heart and Lung Transplantation endorses the management and optimisation of all concomitant (modifiable) conditions to allow listing and improve short- and long-term outcomes after transplant.90 Comorbidities could be separated into two major groups, sarcoidosis-associated comorbidities and treatment-induced comorbidities; this distinction is crucial, as the latter can be preventable. Fatigue is the most frequent condition reported in sarcoidosis and represents a patient priority.91 92 Comorbidities associated with sarcoidosis, including depression, anxiety and obstructive sleep apnoea (OSA) may all contribute to fatigue. Fatigue is a subjective complaint of physical and/or mental exhaustion, and for this reason, it can often be very difficult to differentiate from excessive daily sleepiness.93 Despite an exhaustive search for treatable clinical causes of fatigue, in sarcoidosis fatigue does not correlate with disease activity.92 Its aetiology remains elusive and is usually multifactorial: it may be a consequence of treatment, granulomatous inflammation, psychological disorders or a combination of them, but it may also result from other comorbidities.92 Currently, there is no agreement on the definition of fatigue. Fatigue can be seen and measured as a unidimensional or multidimensional concept. However, specific scales have been developed to measure fatigue in the context of sarcoidosis, in particular the Fatigue Assessment Scale and the Patient-Reported Outcomes Measurement Information System fatigue.94 95 The diagnosis of sarcoidosis-associated fatigue requires an extensive evaluation through a multidisciplinary approach to identify and treat potentially reversible causes. While psychological interventions should always be encouraged, there is some evidence of the potential benefit of various neurostimulants, including methylphenidate and modafinil, for the treatment of sarcoidosis-associated fatigue.96 97 Challenges and future directions of a TT strategy Data regarding the definition and prevalence of TTs in sarcoidosis remain limited, primarily derived from monocentric observational studies.24–28 The variability in the prevalence of specific TTs is influenced by the geographical context of the study, the intensity and type of the diagnostic workup, and the criteria used to characterise and define the traits as clinically significant.39 63 98–100 Moreover, some of the groups of TTs proposed in this manuscript are not entirely distinct and may exhibit considerable overlap or interconnections (eg, obesity, diet, malnutrition). The establishment of international registries that encompass diverse settings and countries is essential for enhancing the precision of prevalence estimates and the characteristics associated with each individual TT. TTs are dynamic in nature, subject to change from year to year or even within a single day, influenced by the disease natural progression or treatment interventions. Furthermore, advancements in technology and pharmaceutical research may modify TTs. Certain TTs necessitate assessment only during follow-up (eg, treatment adherence), while others should be evaluated from the initial visit and consistently reassessed (eg, extrapulmonary involvement). The interactions among clusters of TTs may occur in complex and unpredictable ways, complicating their prioritisation. Consequently, a strategy centred on TTs and priority-setting must be continually reviewed during follow-up. Engaging and involving primary care physicians in the TT strategy is highly advisable.46 Sarcoidosis can affect virtually any organ, underscoring the importance of a comprehensive multidisciplinary management approach. The multidisciplinary team (MDT) has become the diagnostic gold standard in ILDs.64 101 MDTs might potentially improve patient outcomes by enhancing diagnostic accuracy and refining treatment decisions.102 103 In sarcoidosis, the TT approach necessitates active involvement from the MDT in both the diagnostic phase and the identification and management of pertinent TTs. Management and treatment of sarcoidosis might be driven by the most severely affected organ system. MDTs have the potential to optimise patient flow and avoid unnecessary delays in both pharmacological and non-pharmacological interventions, thereby improving patient outcomes.102 103 However, the precise composition of the MDT and the role of the coordinating physician have yet to be established. Table 2 presents proposed key clinical figures that should be included in the MDT along with their specific competencies. Three cases illustrating the role of the MDT in identifying TTs in sarcoidosis are delineated in table 3. Table 2Specialist competencies within the sarcoidosis multidisciplinary care teamSpecialistCompetenciesTreatable trait areas of focusChest physician(coordination of the multidisciplinary team) Diagnosis confirmation and investigation of aetiologyPerformance and evaluation of PFTsBronchoscopyMedication review (side effects of treatment and polypharmacy review)Ensure patient’s adherence to treatmentManagement of respiratory failure, LTOT, NIVIdentification of patients who are candidates for lung transplantIdentification and management of acute exacerbations/progression of diseaseIdentification of patients eligible for RCTsMonitoring of disease severity and potential complicationsEnd-of-life careIdentification of extrapulmonary and referral to the appropriate specialist when necessary EtiologicalLifestylePulmonaryExtrapulmonaryComorbidities Physiotherapist and/or respiratory therapist Pulmonary rehabilitation LifestylePulmonary Nurse Coordinate input of other healthcare professionalsSupport patients and their families to recognise symptoms to avoid complicationsEnsure patient’s adherence to treatment Lifestyle Radiologist Radiological diagnosisIdentification of progressive fibrosisIdentification of AEIdentification of complications AetiologicalComorbidities Gastroenterologist Evaluation and management of extra-respiratory involvementDiagnosis and management of GERDManagement of gastrointestinal side effects of treatment (eg, antifibrotics) ExtrapulmonaryComorbidities Infectious disease specialist Exclude infectious aetiology of granulomatous inflammationAdvice on potential prophylaxis in patients treated with immunosuppressive drugsTreatment of acute and chronic infection AetiologicalPulmonaryComorbidities Cardiologist Diagnosis and management of cardiac sarcoidDiagnosis and management of RHFDiagnosis and management of PH AetiologicalComorbidities Psychologist Management of anxiety and depressionFamily supportEnd-of-life care Lifestyle Endocrinologist Diagnosis and management of osteoporosis and diabetes in patients treated with chronic steroid therapyManagement of endocrinological involvement related to sarcoidosis Comorbidities Nutritionist Diet instruction LifestyleComorbidities Ophthalmologist Screening of ocular involvementManagement of ocular involvementManagement of ocular side effects of systemic steroid therapy ExtrapulmonaryComorbidities Rheumatologist Medication review (side effects of treatment and polypharmacy review)Identification of joint and muscular involvement ExtrapulmonaryComorbidities Geriatrician Identification of frail patientsMedication reviewFamilial and social support LifestyleComorbidities Pharmacologist Medication review (side effects of treatment and polypharmacy review)End-of-life care Pulmonary Thoracic Surgeon Surgical biopsyCo-management of lung cancerLung transplant AetiologicalComorbidities General practitioner Medication review (side effects of treatment and polypharmacy review)Ensure patient’s adherence to treatmentSupport patients and their families to recognise symptoms to avoid complicationsEnd-of-life care LifestylePulmonaryComorbidities AE, acute exacerbation; GERD, gastroesophageal reflux disease; LTOT, long-term oxygen therapy; NIV, non-invasive ventilation; PFT, pulmonary function test; PH, pulmonary hypertension; RCT, randomised controlled trial; RHF, right heart failure. Specialist competencies within the sarcoidosis multidisciplinary care team Diagnosis confirmation and investigation of aetiology Diagnosis confirmation and investigation of aetiology Performance and evaluation of PFTs Performance and evaluation of PFTs Bronchoscopy Bronchoscopy Medication review (side effects of treatment and polypharmacy review) Medication review (side effects of treatment and polypharmacy review) Ensure patient’s adherence to treatment Ensure patient’s adherence to treatment Management of respiratory failure, LTOT, NIV Management of respiratory failure, LTOT, NIV Identification of patients who are candidates for lung transplant Identification of patients who are candidates for lung transplant Identification and management of acute exacerbations/progression of disease Identification and management of acute exacerbations/progression of disease Identification of patients eligible for RCTs Identification of patients eligible for RCTs Monitoring of disease severity and potential complications Monitoring of disease severity and potential complications End-of-life care End-of-life care Identification of extrapulmonary and referral to the appropriate specialist when necessary Identification of extrapulmonary and referral to the appropriate specialist when necessary Etiological Etiological Lifestyle Lifestyle Pulmonary Pulmonary Extrapulmonary Extrapulmonary Comorbidities Comorbidities Pulmonary rehabilitation Pulmonary rehabilitation Lifestyle Lifestyle Pulmonary Pulmonary Coordinate input of other healthcare professionals Coordinate input of other healthcare professionals Support patients and their families to recognise symptoms to avoid complications Support patients and their families to recognise symptoms to avoid complications Ensure patient’s adherence to treatment Ensure patient’s adherence to treatment Lifestyle Lifestyle Radiological diagnosis Radiological diagnosis Identification of progressive fibrosis Identification of progressive fibrosis Identification of AE Identification of AE Identification of complications Identification of complications Aetiological Aetiological Comorbidities Comorbidities Evaluation and management of extra-respiratory involvement Evaluation and management of extra-respiratory involvement Diagnosis and management of GERD Diagnosis and management of GERD Management of gastrointestinal side effects of treatment (eg, antifibrotics) Management of gastrointestinal side effects of treatment (eg, antifibrotics) Extrapulmonary Extrapulmonary Comorbidities Comorbidities Exclude infectious aetiology of granulomatous inflammation Exclude infectious aetiology of granulomatous inflammation Advice on potential prophylaxis in patients treated with immunosuppressive drugs Advice on potential prophylaxis in patients treated with immunosuppressive drugs Treatment of acute and chronic infection Treatment of acute and chronic infection Aetiological Aetiological Pulmonary Pulmonary Comorbidities Comorbidities Diagnosis and management of cardiac sarcoid Diagnosis and management of cardiac sarcoid Diagnosis and management of RHF Diagnosis and management of RHF Diagnosis and management of PH Diagnosis and management of PH Aetiological Aetiological Comorbidities Comorbidities Management of anxiety and depression Management of anxiety and depression Family support Family support End-of-life care End-of-life care Lifestyle Lifestyle Diagnosis and management of osteoporosis and diabetes in patients treated with chronic steroid therapy Diagnosis and management of osteoporosis and diabetes in patients treated with chronic steroid therapy Management of endocrinological involvement related to sarcoidosis Management of endocrinological involvement related to sarcoidosis Comorbidities Comorbidities Diet instruction Diet instruction Lifestyle Lifestyle Comorbidities Comorbidities Screening of ocular involvement Screening of ocular involvement Management of ocular involvement Management of ocular involvement Management of ocular side effects of systemic steroid therapy Management of ocular side effects of systemic steroid therapy Extrapulmonary Extrapulmonary Comorbidities Comorbidities Medication review (side effects of treatment and polypharmacy review) Medication review (side effects of treatment and polypharmacy review) Identification of joint and muscular involvement Identification of joint and muscular involvement Extrapulmonary Extrapulmonary Comorbidities Comorbidities Identification of frail patients Identification of frail patients Medication review Medication review Familial and social support Familial and social support Lifestyle Lifestyle Comorbidities Comorbidities Medication review (side effects of treatment and polypharmacy review) Medication review (side effects of treatment and polypharmacy review) End-of-life care End-of-life care Pulmonary Pulmonary Surgical biopsy Surgical biopsy Co-management of lung cancer Co-management of lung cancer Lung transplant Lung transplant Aetiological Aetiological Comorbidities Comorbidities Medication review (side effects of treatment and polypharmacy review) Medication review (side effects of treatment and polypharmacy review) Ensure patient’s adherence to treatment Ensure patient’s adherence to treatment Support patients and their families to recognise symptoms to avoid complications Support patients and their families to recognise symptoms to avoid complications End-of-life care End-of-life care Lifestyle Lifestyle Pulmonary Pulmonary Comorbidities Comorbidities AE, acute exacerbation; GERD, gastroesophageal reflux disease; LTOT, long-term oxygen therapy; NIV, non-invasive ventilation; PFT, pulmonary function test; PH, pulmonary hypertension; RCT, randomised controlled trial; RHF, right heart failure. Table 3Three illustrative cases of patients with sarcoidosis treated according to the TT strategyCase historyA female in her 70s with pulmonary sarcoidosis presents to the clinic with a chronic cough and exertional breathlessness. She is a former smoker of 30 pack years, has a BMI of 35 and reports a history of CAD, osteopenia and GERD. She is currently treated with prednisone 15 mg daily, PPI and antiplatelet therapy. She has been on prednisone since the diagnosis of sarcoidosis was confirmed on transbronchial biopsy 3 years ago. Almost 1 year ago, she was treated with methotrexate which was discontinued due to hepatic toxicity. She has suffered from increasing exertional breathlessness that limits her daily activities and reports sleep-related choking episodes for the last year. She has recently avoided contact with family and friends due to her clinical status. She underwent an HRCT scan 2 months ago with evidence of progression of fibrosis, with the appearance of honeycombing and increased evidence of traction bronchiectasis. The spirometry shows a 400 mL decrease in the FVC over the past 12 months but a slight decline in DLCO. Her 6-minute walk distance is 24% of the predicted value with exercise-induced respiratory failure. The SGRQ score is 73. An ABG reveals hypoxaemia with normocapnia. Treatable traits Specialist of the multidisciplinary care team involved in diagnosis and treatment Individualised treatment LifestyleDeconditioning of skeletal muscleChest physicianPhysiotherapistPulmonary rehabilitationLong-term oxygen therapyPulmonaryProgressive fibrosisChest physicianRadiologistAntifibrotic drugsChronic respiratory failureChest physicianPhysiotherapistLong-term oxygen therapyPulmonary rehabilitationComorbiditiesGERDGastroenterologistNutritionistPrimary care physicianDiet instructionsPro-kinetic drugsOSAChest physicianNutritionistDiet instructionsCPAP treatmentObesityNutritionistPhysiotherapistPrimary care physicianDiet instructionsExercise trainingDepressionPsychologistAntidepressant drugsCognitive behavioural therapyOsteopeniaEndocrinologistPrimary care physicianBone protection medicationsFrailtyChest physicianPhysiotherapistPsychologistPrimary care physicianNutritional supportivePulmonary rehabilitationPhysical activity programmesOutcomes assessment at baseline and after the individualised TT approach Baseline 3 months12 monthsSGRQ736550FVC % predicted5050486MWD metres100120200GERDDaily symptomsOvernight symptomsNo symptomsBMD T-score−1.6/−1.5BMI3534.529.5K-BILD656045FAS665AHI3411 Case history A man in his 50s with sarcoidosis presents to the clinic with a chronic productive cough and exertional breathlessness. He is a former smoker of 25 pack-years and has a BMI of 16.7. He is currently treated with a PPI and low-dose steroid that was started 3 years ago when the diagnosis was made. However, adherence to steroid treatment is low due to concerns about the risk of diabetes and the development of insomnia.Over the past 12 months, he has experienced four episodes of respiratory low-tract infections treated with oral antibiotics. Sputum cultures grew Haemophilus influenzae during only one of the four episodes, and two prior sputum samples taken during clinical stability confirmed the absence of micro-organisms.An HRCT 3 months before the clinic visit showed stable diseases, with evidence of nodules within the lung, intralobular reticulation and diffuse cylindrical bronchiectasis.FVC has been stable over the past 12 months. FEV1 has been progressively worsening during the last year (from 42% to 35% of the predicted value), with a forced expiratory ratio of 0.55 suggestive of airflow obstruction but without a bronchodilator response. DLCO has been stable over the last 12 months. His 6-minute walk distance is 84% of the predicted value. Treatable traits Specialist of the multidisciplinary care team involved in diagnosis and treatment Individualised treatment LifestyleAdherence to treatmentChest physicianNursePrimary care physicianEducationWritten instructionsSelf-management planFamily and social supportPulmonaryRecurrent infectionsChest physicianPhysiotherapistInfectious disease specialistPrimary care physicianMucociliary clearance techniques with a physiotherapistPulmonary rehabilitationAirway obstructionChest physicianPhysiotherapistBronchodilatorsComorbiditiesCachexiaChest physicianNutritionistPrimary care physicianDiet instructionPulmonary rehabilitationOutcomes assessment at baseline and after the individualised TT approach Baseline 3 months12 monthsSGRQ535048FVC % predicted555758FEV1 % predicted353939Exacerbations/year4/1Adherence to treatmentSub-optimalOptimalOptimalBMI16.71719 Case history A man in his 30s was hospitalised due to high-grade atrioventricular block and subsequent syncope. His medical history was negative, but he had noted worsening diffuse arthralgias in the last 2 months before hospitalisation. Echocardiography showed only a mildly reduced left ventricular systolic function. Segmental contraction abnormalities were detected on cardiac MRI. A total body CT scan during hospitalisation revealed mediastinal lymphadenopathy and bilateral pulmonary nodules. Bronchoscopy with lavage and an EBUS transbronchial needle biopsy of the mediastinal lymph node was performed and confirmed the diagnosis of sarcoidosis. Screening for other organ involvement was normal and lung function tests were normal.The patient remained on systemic steroids for 2 years with good clinical response and no signs of relapse after discontinuation of therapy.After 4 years from diagnosis, the patient presented to the outpatient clinic with fatigue and diffuse arthralgias; thus he had noted worsening exertional dyspnoea and chronic cough. Peripheral bilateral oedema of the lower limbs was noted during physical examination. Diagnostic workup shows relapse of cardiac sarcoidosis and worsening pulmonary involvement with miliariform distribution on HRCT scan. The lung function test now shows a restrictive defect with low DLCO values. Blood gas analysis shows mild hypoxaemia while 6MWT is positive for exercise-induced respiratory failure. Treatable traits Specialist of the multidisciplinary care team involved in diagnosis and treatment individualised treatment PulmonaryNon-fibrotic involvementChest physicianRadiologistHigh-dose steroidsRelapsing diseasesChest physicianRadiologistHigh-dose steroidsChronic respiratory failureChest physicianOxygen therapyVentilatory defectsChest physicianPhysiotherapistHigh-dose steroidsPulmonary rehabilitationIntractable chronic coughChest physicianPrimary care physicianHigh-dose steroidsThalidomideExtrapulmonary involvementMyocarditisCardiologistRadiologistHigh-dose steroidsICDMuscular/skeletalRheumatologistPhysiotherapistHigh-dose steroidsRehabilitationOutcomes assessment at baseline and after the individualised TT approach Baseline 3 months 1 year SGRQ658595FVC % predicted5275105FEV1 % predicted5670109DLCO507090Exercise induced respiratory failurePresentNoNoExacerbations/year100LCQ71320FAS252215EF on echocardiography and cardiac MRI35%55%55%In each box are reported the pharmacological and non-pharmacological treatments identified by the multidisciplinary team and the hypothetical benefits of treatment assessed at 3 months and 1 year follow-up, intended to exemplify the potential application of the TT approach rather than represent real patient data or case report evidence.ABG, arterial blood gas analysis; AHI, Apnoea-Hypopnoea Index; BMD, bone mass density; BMI, body mass index; CAD, coronary artery disease; CPAP, continuous positive airway pressure; DLCO, diffusion lung capacity for carbon monoxide; EBUS, endobronchial ultrasound; EF, ejection fraction; FAS, Fatigue Assessment Scale; FEV1, forced expiratory volume in the 1 s; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; HRCT, high resolution CT; ICD, implantable cardioverter defibrillator; K-BILD, King’s Brief Interstitial Lung Disease Questionnaire; LCQ, Leicester Cough Questionnaire; 6MWTD, 6-minute walking test distance; OSA, obstructive sleep apnoea; PPI, proton pump inhibitor; SGRQ, St George’s Respiratory Questionnaire. Three illustrative cases of patients with sarcoidosis treated according to the TT strategy In each box are reported the pharmacological and non-pharmacological treatments identified by the multidisciplinary team and the hypothetical benefits of treatment assessed at 3 months and 1 year follow-up, intended to exemplify the potential application of the TT approach rather than represent real patient data or case report evidence. ABG, arterial blood gas analysis; AHI, Apnoea-Hypopnoea Index; BMD, bone mass density; BMI, body mass index; CAD, coronary artery disease; CPAP, continuous positive airway pressure; DLCO, diffusion lung capacity for carbon monoxide; EBUS, endobronchial ultrasound; EF, ejection fraction; FAS, Fatigue Assessment Scale; FEV1, forced expiratory volume in the 1 s; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; HRCT, high resolution CT; ICD, implantable cardioverter defibrillator; K-BILD, King’s Brief Interstitial Lung Disease Questionnaire; LCQ, Leicester Cough Questionnaire; 6MWTD, 6-minute walking test distance; OSA, obstructive sleep apnoea; PPI, proton pump inhibitor; SGRQ, St George’s Respiratory Questionnaire. Incorporating patient preferences and values into a TT strategy for sarcoidosis is crucial. Effective communication and development of a shared management plan with patients serve as fundamental drivers of medication adherence. Adherence to treatment, particularly corticosteroids, is often limited in sarcoidosis, while greater adherence correlates with improved QoL.19 39 A recent survey conducted by the European Lung Foundation among patients with sarcoidosis from nine countries indicated that respondents emphasised the need to include QoL as a relevant outcome within their management plan.104 Evidence from other chronic pulmonary conditions has shown enhanced outcomes when patients participate in the decision-making process with targeted patient-reported outcome measures (PROMs).105 The varying levels and types of QoL impairment reflect the heterogeneous nature of sarcoidosis. A structured application of PROMs within the TT approach can effectively identify treatment effects on patients’ well-being. One significant barrier to effective sarcoidosis treatment is the scarcity of biomarkers and endotypes. Several HLA haplotypes and SNPs have been linked to the onset and clinical manifestations of the disease.9 106 107 Conversely, certain genetic polymorphisms may account for variability in treatment responses.108 109 As discussed before, patients carrying chronic-associated HLA types may benefit from early initiation of immunomodulatory therapies such as TNF-α inhibitors or JAK-STAT pathway modulators, but this is currently speculative. Nonetheless, many biomarkers are constrained by their lack of specificity, as they are associated with broad immune activities across multiple diseases. The identification of biomarkers, using artificial intelligence and machine learning methodologies, may yield more informative insights than isolated markers. In this context, sarcoidosis may serve as a model for applying precision medicine in immune-mediated diseases, transforming treatment paradigms from reactive to preventive and targeted interventions based on genetic susceptibility. Finally, the TT approach may be more readily implemented in countries with robust healthcare systems and established multidisciplinary networks, but it poses challenges in resource-limited settings with restricted access to diagnostic tests and serum biomarkers. Clinicians in such environments may face several obstacles, adversely affecting doctor–patient communication and, consequently, treatment adherence. Additionally, concerns regarding the potential costs associated with implementing the TT approach warrant thorough consideration. While initial investments in clinical research may be necessary, it can be reasonably hypothesised that lifetime costs could decrease due to improvements in clinical outcomes. Conclusion The proposed TT strategy for sarcoidosis relies on various phenotypes and key clinical characteristics of the disease. Enhancing our understanding of the pathophysiology through additional genetic and etiological components is essential for identifying the endotypes of sarcoidosis and improving clinical care for patients. To implement this strategy effectively, a multidisciplinary approach is required, which addresses not only systemic and pathophysiological factors but also the somatic and psychosocial dimensions of the disease. Globally, the challenges associated with sarcoidosis are primarily linked to disease management and patient engagement. Patient-centred medicine has evolved into 5P medicine, which aims to identify the clinically relevant TTs that should be targeted to address the patient needs.110 Figure 1 provides a conceptual framework linking TTs with the 5P medicine approach, rather than a representation of validated clinical pathways. 5P Medicine refers to a modern approach to healthcare that is Predictive, Preventive, Personalised, Participatory and Proactive. It aims to use data, technology, and patient involvement to anticipate disease, tailor treatments and improve overall health outcomes.110–112 The 5P framework signifies a transition towards proactive and tailored healthcare, moving beyond a traditional reactive one.111 The 5P medicine emphasises the use of predictive technologies to identify disease risks, implement preventive measures, encourage patient participation and personalise treatments based on individual characteristics.112 Precision medicine also focuses on tailoring treatments to a person’s unique genetic makeup and other prognostic factors.83 Empowering patients in the decision-making process transforms them from passive recipients of care into active participants in their treatment and management. In sarcoidosis, the 5P framework has the potential to translate into more effective and sustainable management strategies. A diverse range of treatable traits (TTs) can be present within a single patient, presenting both unique challenges and significant opportunities for personalised care. Each TT is colour-coded to reflect its importance, measurability and treatability for the individual patient. This colour-coding allows healthcare providers to quickly discern which TTs require immediate attention and which can be monitored over time. While some proposed TTs are of profound clinical relevance and may be straightforward to assess or treat, others may pose challenges in identification and management. Furthermore, every aspect of the 5P model—Predictive, Preventive, Participatory, Personalised and Proactive—interacts dynamically with each TT, influencing its significance and the potential for effective treatment. For example, the first woman on the left illustrates how certain TTs may have minimal clinical relevance yet can be easily prevented, emphasising the impact of tailored interventions in healthcare. QoL, quality of life; PROMs, patient-reported outcome measures. Further RCTs based on TTs are necessary to optimise both non-pharmacological and pharmacological interventions that focus on phenotype- and endotype-driven mechanisms, with the goal of improving QoL and outcomes for patients with sarcoidosis. We believe this approach will also enhance awareness of the disease among healthcare providers, regulatory agencies, and patient advocacy groups.